TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06763471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuropixels recording intraoperatively during planned neurosurgery
Description: The SUNAN study is a basic science study involving a procedure to record single-unit neurophysiological activity with human participants who are already undergoing a transcranial neurosurgical procedure on the brain.~As part of the surgery, a region of cerebral cortex on the convexity of the brain will be:~* Resected e.g., as removal of part of a tumour or epilepsy focused. Or~* Transgressed as part of the surgical approach to reach a deeper target e.g., resection of a deep tumour or cavernoma.~Or~• Transgressed by the passage of a surgical implant e.g., a ventriculoperitoneal shunt catheter or deep brain stimulation electrode.~Within this region of the brain that is going to be resected or transgressed, the research team will undertake a single-unit resolution neurophysiological recording (NR) using a digital neural probe (Neuropixels) for a maximum of 15 minutes.
Study: NCT06764108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Self-monitoring will involve completing one brief smartphone-based survey (at a fixed time) per day on suicidal thoughts and related affect states and experiences over the past day during the four weeks after psychiatric hospitalization.
Study: NCT06203041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Orally administered, daily dose of 5000 IU (125 mcg) Vitamin D3 for 28 days.
Study: NCT06763094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium dobesilate (Doxium)
Description: This intervention is unique because Calcium Dobesilate is not a hormonal agent and does not carry the risks associated with hormonal therapies, such as potential impact on fertility or long-term endocrine effects. Additionally, it may be more suitable for patients who cannot tolerate hormonal treatments due to contraindications such as previous thrombotic events or risk factors for thrombosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid stands out due to its non-hormonal action in managing menorrhagia, providing an alternative for women who are contraindicated for hormonal treatments or prefer non-hormonal solutions. Unlike other hormonal treatments, Tranexamic Acid does not impact fertility or have significant endocrine effects.
Study: NCT06763029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposomes combined with cetuximab + vermofenib
Description: Vermofenil 960mg orally twice daily; Irinotecan liposomes, 70mg/m2, d1, 90 min intravenously, Q2W; Cetuximab 500mg/m2, d1, Q2W;
Study: NCT06762782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant lenvatinib
Description: Follow the instructions and take lenvatinib 8 mg (body weight ≤ 60Kg) or 12 mg (body weight ≥ 60Kg) orally once a day.

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care measures
Description: Adjuvant treatments such as antiviral, TACE, HAIC, radiotherapy, and systemic antitumor therapy can be used
Study: NCT06763926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Triptorelin
Description: Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the control group, 200 mcg subcutaneous triptorelin will be administered 34-36 hours prior to planned oocyte collection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal nafarelin
Description: Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the experimental group, 800 mcg intranasal nafarelin will be administered 34-36 hours prior to planned oocyte collection.
Study: NCT06764758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment
Description: Root-canal therapy applied in asymptomatic teeth with deep carious lesion required endodontic treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorative treatment
Description: Composite resin restoration applied in teeth previously applied endodontic treatment.
Study: NCT06763536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide Measurement
Description: Undergo carbon monoxide measurement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo carbon monoxide measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive daily check-ins via smartphone application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Receive daily check-ins via smartphone application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: Use nicotine lozenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Use oral nicotine pouch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Use nicotine patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06764823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: In the cryotherapy group, after completing the biomechanical preparation, the root canals will be irrigated with 5 mL of 0.9% physiological saline solution at 2.5°C for 5 minutes; the solution will be stored in the refrigerator until use.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: In the control group, the final irrigation will be performed using 5 mL of 0.9% physiological saline solution at room temperature for 5 minutes.
Study: NCT06763679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: Acromioclavicular joint mobilization:~* The patient is placed in the supine position and the upper limb is placed in a physiological position with the patient's arm clinging to the body and the hand on the abdomen, which causes the capsule to stretch less and the technique to be less painful.~* The therapist placed the tips of his both thumbs on the anterior surface of the clavicle adjacent to the ACJ and spread his other fingers out for stability and his forearm was situated in line with the posterior movement at the ACJ.~* ACJ mobilization was performed in up to 30-minute individual sessions by a single trained therapist.~* The treatment techniques were anterior to posterior passive accessory glides of the distal end of the clavicle categorized from Grade III~* Grade III is used at a large amplitude from the middle of the joint ROM to the start of the constraint. Grade III will apply for stimulating a stretching to relieve joint stiffness in a shorter tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy
Description: Spencer technique:~* The patient was resting on their side, with the affected shoulder raised.~* In 7 separate movements, the therapist used the proximal hand to stabilize the shoulder girdle, while the distal hand applied force to the restrictive barrier of the shoulder.~* Shoulder extension, circumduction with compression, shoulder flexion, circumduction with distraction, abduction, adduction with internal rotation, and glenohumeral pump were the exercises performed.~* The patients were advised to employ their muscle energy technique against the small resistance provided by the therapist for 3-5 seconds throughout each movement.~* Over the course 5 days a week, the exercise was repeated 3-5 times per session, with rest breaks.
Study: NCT06762808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given by IV infusion
Study: NCT06763055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg
Description: The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg
Description: The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine Mesylate
Description: The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine Mesylate
Description: The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (Standard treatment)
Description: The group will not receive deferoxamine mesylate or colchicine
Study: NCT06763887

Intervention type: OTHER
Intervention: No Interventions
Description: No intervention
Study: NCT06763133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Water Spray Application
Description: Cold water spray application after endonasal endoscopic surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical routine practice
Description: The process of giving 2 cc of water to patients with a syringe as a clinical routine practice.
Study: NCT06762951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates mat exercices
Description: Pilates mat exercise which consists of (single leg stretch + Pelvic press + Swimming + Opposite arm and leg reach + Side to side), 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental control exercises
Description: Segmental control exercise which consists of (Segmental control over primary stabilizers, Exercises in closed chain, and Exercises in open chain)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: Traditional physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl-up exercise in supine, Back extensors exercise in prone, and Hip extensors exercises in prone along with ultrasound and Transcutaneous electrical nerve stimulation (TENS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: Traditional physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl-up exercise in supine, Back extensors exercise in prone, and Hip extensors exercises in prone along with ultrasound and Transcutaneous electrical nerve stimulation (TENS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Traditional physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl-up exercise in supine, Back extensors exercise in prone, and Hip extensors exercises in prone along with ultrasound and Transcutaneous electrical nerve stimulation (TENS)
Study: NCT06762847

Intervention type: DEVICE
Intervention: Use of Conventional Silicone Prosthetic Liner
Description: At this stage participant who will be fitted with a standard silicone liner typically used for transtibial prosthetics. Over a set duration, we will assess the liner's performance, particularly in terms of durability, comfort, skin health, and fit stability. Acting as the control group, this cohort will provide essential baseline data for comparison with the innovative prosthetic liner.
Study: NCT06764238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab (Group A)
Description: For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (nonRand Group)
Description: For I/HR patients non eligible for blinatumomab randomization, venetoclax+ mini-hyperCVD will be applied after PVDL induction, subsequently followed by CAT as intensification, interim continuation, late intensification, and maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab (Group B)
Description: For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy
Study: NCT06762730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 5 mg/Bag 100 ml Inj
Description: Zolendric acid will be provided to HIV naïve patients with documented osteopnia
Study: NCT06762925

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions
Study: NCT06763939

Intervention type: OTHER
Intervention: RT00401-GO0046
Description: Cosmetic care product

Intervention type: OTHER
Intervention: RT00401-GA0677
Description: Placebo cosmetic care product
Study: NCT06764186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Study: NCT06762873

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug Induced Sleep Endoscopy with PNS
Description: Enrolled subjects will complete an overnight PSG and then undergo a DISE procedure with a 30-minute research period.
Study: NCT06763874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-based FES device
Description: One session of one hour to execute task-oriented exercises with the upper limb while wearing the EMG-based FES device. Submission of questionnaires related to usability, acceptance and satisfaction of the device.
Study: NCT06763419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External low level laser therapy
Description: Patients received 8 sessions of external diode laser (635 nm).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal low level laser therapy
Description: Patients received 8 diode laser (635 nm) sessions applied internally
Study: NCT05679063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham, Control
Description: Talks about healthy habits
Study: NCT06506422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: 10mg Empagliflozin daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg Placebo daily for 12 weeks
Study: NCT03955627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)
Description: Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
Study: NCT05906563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin gel
Description: local application of Melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and melatonin gel
Description: local application of Metformin and melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Local application of empty nanoparticles gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planning
Description: full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planning
Description: full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: scaling and root planning
Description: full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planning
Description: full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.
Study: NCT06320626

Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - PK-guided dose reduction
Description: PK-guided dose reduction emicizumab targeted at a Ctrough of 30μg/mL.

Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - PK-guided dose reduction
Description: PK-guided dose reduction emicizumab targeted at a Ctrough of 30μg/mL.

Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - Dosis continuation group
Description: Continue on their current dose regimen

Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - Dosis continuation group
Description: Continue on their current dose regimen

Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - Dose adjustment group
Description: Adjusted in dosing regimen according to local protocol

Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - Dose adjustment group
Description: Adjusted in dosing regimen according to local protocol
Study: NCT05395988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital hand washing instructions
Description: Tablet displaying animated hand washing instructions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital hand washing instructions
Description: Tablet displaying animated hand washing instructions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital hand washing reward
Description: Tablet displaying animated hand washing instructions and animated animals as reward

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital hand washing reward
Description: Tablet displaying animated hand washing instructions and animated animals as reward
Study: NCT04829721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention with video
Description: Women randomized to an educational video workshop group.
Study: NCT05848921

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test
Study: NCT05599802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 variant mRNA vaccine low dose
Description: 50μg/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 variant mRNA vaccine low dose
Description: 50μg/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 variant mRNA vaccine low dose
Description: 50μg/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 variant mRNA vaccine high dose
Description: 100μg/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 variant mRNA vaccine high dose
Description: 100μg/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 variant mRNA vaccine high dose
Description: 100μg/dose